Immunovia AB
IMMNOV.ST
Get informed when a big investor buys or sells
+ FollowMarket Cap$27.06M
Close$
$0.22
176.5% upside
Current Fair Value
176.5% upsideUndervalued by 176.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $27.06 Million |
|---|---|
| Enterprise Value | $-1,329,478.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.42 |
| Beta | 2.73 |
| Outstanding Shares | 672,666,892 |
Return
| Return on Equity | -372.43% |
|---|---|
| Return on Assets | -183.25% |
| Return on Invested Capital | -251.03% |
Valuation & Multiples
| P/E Ratio | -0.47 |
|---|---|
| PEG | 1.06 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -1.1 |
| Enterprise Value to EBIT | 0.02 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -4.9 |
| Debt to Equity | 0.28 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.04
Average shareholder expectationRevenue Estimate
$400,000
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.02
Average shareholder expectationRevenue Estimate
$500,000
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Immunovia AB
13 employees
CEO: Jeff Borcherding Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indica...